Department of Gastroenterology and Hepatology, Musashino Red-Cross Hospital, Tokyo, Japan.
J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:115-22. doi: 10.1111/j.1440-1746.2010.06543.x.
Hepatocellular carcinoma (HCC) is the third leading cause of death in the malignant neoplastic diseases in the world. Surgical operation is sometimes not indicated because of complicated liver cirrhosis and extrahepatic disorders. Radiofrequency ablation has been developed as a less invasive treatment for HCC since 1999, and long-term outcome has been shown. There are several complications which should be paid attention, and to improve the prognosis, combination treatment with transarterial chemoembolization should be discussed. Overall survival after between RFA and surgical resection should be compared prospectively. Establishment of staging system for treatment allocation of HCC and prevention of HCC recurrence is important issue to be examined.
肝细胞癌（HCC）是全球恶性肿瘤疾病导致死亡的第三大主要原因。由于复杂的肝硬化和肝外疾病，手术有时不适用。自 1999 年以来，射频消融已被开发为 HCC 的一种微创治疗方法，并且已经显示出长期结果。有几种并发症需要注意，为了改善预后，应该讨论与经动脉化疗栓塞的联合治疗。RFA 和手术切除后的总生存时间应该进行前瞻性比较。建立 HCC 的治疗分配分期系统和预防 HCC 复发是需要研究的重要问题。
